MEX-CD1 extracorporeal iron chelation device

Current understanding

To be populated as evidence accumulates.

2026-04-23 — Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis: MEXIRON feasibility trial (early-phase) evaluates MEX-CD1 device delivering three low-volume continuous veno-venous haemodialysis cycles within one week in transfusion-dependent MDS/MF patients, with primary endpoints of serum iron reduction, transfusion needs, QoL, and safety assessed at 7, 28, and 90 days — positioned as a first-in-class alternative to oral iron chelation. (novelty: 4)